To test this hypothesis, we explored the effect of the clinically relevant Wee1 inhibitor adavosertib in an established isogenic GBM cell line model system with and without endogenous EGFRvIII expression demonstrating different TP53 status alone and in combination with x-irradiation. This evidence concerns the gene WEE1 and glioblastoma.